Summit Therapeutics Inc（SMMT）资讯与事件SMMTSummit Therapeutics Inc

Summit Therapeutics and Lunit Sign Research Agreement

Summit Therapeutics and Lunit announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment analysis in support of Summit's immuno-oncology development programs with ivonescimab. The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained whole-slide images to characterize tumor microenvironment features. The companies aim to explore how AI-powered pathology analysis can support biomarker discovery, patient stratification or selection, and a deeper biological understanding of response to ivonescimab therapies. Summit is developing ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in several solid tumors. Lunit SCOPE IO is designed to support immuno-oncology research and biomarker development through AI-powered analysis of H&E slides, enabling scalable assessment of tumor microenvironment features without requiring additional stains or assays. "Understanding the tumor microenvironment is increasingly important as immuno-oncology moves beyond single-axis checkpoint inhibition toward more complex mechanisms and combinations," said Allen Yang, MD, PhD, Chief Research and Development Strategy Officer of Summit. "We are pleased to work with Lunit to explore how AI-powered pathology can help generate deeper, more scalable insights from routine tissue samples and inform the continued development of ivonescimab."

Summit Therapeutics Collaborates with ECOG-ACRIN on Biliary Tract Cancer Trial

Summit Therapeutics announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group to evaluate ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in a registration-enabling Phase II/III study in biliary tract cancer. The new study, EA2251, is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab plus chemotherapy in the first-line treatment of patients with advanced BTC. The open-label Phase II/III EA2251 study plans to enroll patients in the U.S. who will be randomized to receive ivonescimab in combination with gemcitabine and cisplatin, or pembrolizumab or durvalumab in combination with gemcitabine and cisplatin as the established standard-of-care comparator regimen. The primary endpoint for the study is overall survival. Activation of clinical trial sites is expected to begin in the fourth quarter of 2026.

Summit Therapeutics Options Volume Normal, Implied Volatility at 4.1%

Pre-earnings options volume in Summit Therapeutics is normal with calls leading puts 19:6. Implied volatility suggests the market is anticipating a move near 4.1%, or 64c, after results are released. Median move over the past eight quarters is 11.0%.